ASCT for AL: All's well that ends well

Blood

Volumn 118, Issue 16, 2011, Pages 4298-4299

  Wechalekar, Ashutosh D ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; AMYLOID PROTEIN; BORTEZOMIB; CALRETICULIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; MELPHALAN; THALIDOMIDE;

AGE; AMYLOID LIGHT CHAIN AMYLOIDOSIS; AMYLOIDOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CLINICAL TRIAL (TOPIC); DISEASE CONTROL; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG RESPONSE; EVENT FREE SURVIVAL; HUMAN; LIGHT CHAIN; NOTE; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; RELAPSE; REMISSION; SURVIVAL TIME; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 80054836397     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-08-375105     Document Type: Note

References (10)

1. Cibeira MT, Sanchorawala V, Seldin DC, et al. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood. 2011;118(16):4346-4352.
2. Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood. 2002;99(12):4276-4282. (Pubitemid 34627192)
3. Jaccard A, Moreau P, Leblond V, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. NEngl J Med. 2007;357(11):1083-1093. (Pubitemid 47443213)
4. Palladini G, Perfetti V, Obici L, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood. 2004;103(8):2936-2938. (Pubitemid 38451663)
5. Reece DE, Hegenbart U, Sanchorawala V, et al. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood. 2011;118(4):865-873.
6. Zonder JA, Sanchorawala V, Snyder RM, et al. Melphalan and dexamethasone plus bortezomib induces hematologic and organ responses in AL-amyloidosis with tolerable neurotoxicity [abstract]. ASH Annual Meeting Abstracts. 2009;114:746.
7. Wechalekar AD, Kastritis E, Merlini G, et al. A European collaborative study of treatment outcomes in 428 patients with systemic AL amyloidosis [abstract]. ASH Annual Meeting Abstracts. 2010;116:988.
8. Sanchorawala V, Quillen K, Sloan JM, Andrea NT, Seldin DC. Bortezomib and high dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study [published online ahead of print August 22, 2011]. Haematologica. doi:10.3324/haematol-2011-049858.
9. Lee C, Guinn BA, Brooks SE, Richardson D, Orchard K. CD66a (CEACAM1) is the only CD66 variant expressed on the surface of plasma cells in multiple myeloma: a refined target for radiotherapy trials? Br J Haematol. 2010;149(5): 795-796.
10. Zhou P, Teruya-Feldstein J, Lu P, Fleisher M, Olshen A, Comenzo RL. Calreticulin expression in the clonal plasma cells of patients with systemic light-chain (AL) amyloidosis is associated with response to high-dose melphalan. Blood. 2008;111(2):549-557.